AR122725A1 - Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos - Google Patents

Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos

Info

Publication number
AR122725A1
AR122725A1 ARP210101737A ARP210101737A AR122725A1 AR 122725 A1 AR122725 A1 AR 122725A1 AR P210101737 A ARP210101737 A AR P210101737A AR P210101737 A ARP210101737 A AR P210101737A AR 122725 A1 AR122725 A1 AR 122725A1
Authority
AR
Argentina
Prior art keywords
alkyl
unsubstituted
substituted
cycloalkyl
halogen
Prior art date
Application number
ARP210101737A
Other languages
English (en)
Spanish (es)
Inventor
Matthew D Alexander
Matthew D Correa
Deepak Dalvie
Virginia Heather Sharron Grant
Joshua Hansen
Iii Roy L Harris
Evan J Horn
Dehua Huang
Christopher Mayne
Stephen Norris
Veronique Plantevin-Krenitsky
John J Sapienza
Lida Tehrani
Brandon W Whitefield
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AR122725A1 publication Critical patent/AR122725A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ARP210101737A 2020-06-24 2021-06-23 Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos AR122725A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063043612P 2020-06-24 2020-06-24

Publications (1)

Publication Number Publication Date
AR122725A1 true AR122725A1 (es) 2022-09-28

Family

ID=79032406

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101737A AR122725A1 (es) 2020-06-24 2021-06-23 Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos

Country Status (9)

Country Link
US (2) US11739075B2 (cg-RX-API-DMAC7.html)
EP (1) EP4171568B1 (cg-RX-API-DMAC7.html)
JP (1) JP7778095B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230027213A (cg-RX-API-DMAC7.html)
CN (1) CN115955979B (cg-RX-API-DMAC7.html)
AR (1) AR122725A1 (cg-RX-API-DMAC7.html)
ES (1) ES3048462T3 (cg-RX-API-DMAC7.html)
TW (1) TW202216681A (cg-RX-API-DMAC7.html)
WO (1) WO2021262812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
IL299256A (en) 2020-06-24 2023-02-01 Celgene Corp Cerebellum binding compounds, their compounds and methods of treatment with them
ES3047718T3 (en) 2020-06-24 2025-12-04 Celgene Corp Cereblon binding compounds, compositions thereof, and methods of treatment therewith
WO2022262782A1 (zh) * 2021-06-17 2022-12-22 南京明德新药研发有限公司 戊二酰亚胺取代的异噁唑稠环化合物及其应用
US20240408085A1 (en) 2021-09-01 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Compound for degradation of bcl-2 family proteins and medical application thereof
KR20250020448A (ko) 2022-06-02 2025-02-11 시젱 하이스코 파마수티칼 씨오., 엘티디. Bcl6을 억제하거나 분해하는 화합물 및 의약학에서의 응용
TW202530189A (zh) 2023-09-29 2025-08-01 日商第一三共股份有限公司 3-苯基丙基胺衍生物
CN122497677A (zh) 2023-10-20 2026-07-31 奇树医药公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
WO2008101030A1 (en) * 2007-02-13 2008-08-21 The Regents Of The University Of California Methods for amplifying steroid hormone effects
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
WO2015179434A1 (en) * 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule ras inhibitors
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN110317192A (zh) * 2018-03-28 2019-10-11 上海美志医药科技有限公司 一类具有降解雄激素受体活性的化合物
BR112021011968A2 (pt) 2018-12-19 2021-09-08 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
AU2019404022A1 (en) 2018-12-19 2021-07-08 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
IL299256A (en) 2020-06-24 2023-02-01 Celgene Corp Cerebellum binding compounds, their compounds and methods of treatment with them
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
ES3047718T3 (en) 2020-06-24 2025-12-04 Celgene Corp Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
EP4171568B1 (en) 2025-08-27
US11739075B2 (en) 2023-08-29
US20210403453A1 (en) 2021-12-30
WO2021262812A1 (en) 2021-12-30
ES3048462T3 (en) 2025-12-10
EP4171568A1 (en) 2023-05-03
JP2023531709A (ja) 2023-07-25
CN115955979B (zh) 2025-12-05
KR20230027213A (ko) 2023-02-27
US12227490B2 (en) 2025-02-18
JP7778095B2 (ja) 2025-12-01
US20230348431A1 (en) 2023-11-02
EP4171568A4 (en) 2024-07-24
CN115955979A (zh) 2023-04-11
TW202216681A (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
AR122723A1 (es) Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos
AR122726A1 (es) Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos
PE20221336A1 (es) Compuestos triciclicos sustituidos
PE20200758A1 (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3
AR115296A1 (es) Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
AR113909A1 (es) Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b
AR088061A1 (es) Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
AR110706A1 (es) Inhibidores de poli-adp ribosa polimerasa (parp)
AR103828A1 (es) INHIBIDORES DEL FACTOR TRANSFORMADOR DEL CRECIMIENTO b
AR083058A1 (es) Compuestos de estructura de imidazotriazinona
AR060633A1 (es) Derivados de furo[3, 2-d]pirimidina, furo[2, 3-d]pirimidina, tieno[3, 2-d]pirimidina y tieno[2, 3-d]pirimidina, metodos para su preparacion, composiciones farmaceuticas y obtencion de las mismas, el uso de estos derivados en la fabricacion de medicamentos, kits y productos para el tratamiento de enf
AR092288A1 (es) Ligandos del receptor ep1
AR119728A1 (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
AR116114A1 (es) Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
AR087628A1 (es) Inhibidores de pde10 de pirimidina
AR079689A1 (es) Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias.
AR096332A1 (es) Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih
AR094876A1 (es) Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR110298A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR119376A1 (es) Compuestos heterocíclicos
AR081960A1 (es) Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
PE20161379A1 (es) Nuevos compuestos macrociclicos
PE20081113A1 (es) Inhibidores virales policiclicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal